Publications

  1. Rogers LM, Mott SL, Smith BJ, Link BK, Sahin D, Weiner GJ. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clin Cancer Res. 2017 Feb 15; 23 (4):954-961 Epub 2016 Aug 15
    View PubMed
  2. Sun Z, Yu W, Sanz Navarro M, Sweat M, Eliason S, Sharp T, Liu H, Seidel K, Zhang L, Moreno M, Lynch T, Holton NE, Rogers L, Neff T, Goodheart MJ, Michon F, Klein OD, Chai Y, Dupuy A, Engelhardt JF, Chen Z, Amendt BA. Sox2 and Lef-1 interact with Pitx2 to regulate incisor development and stem cell renewal. Development. 2016 Nov 15; 143 (22):4115-4126 Epub 2016 Sept 22
    View PubMed
  3. Riordan JD, Drury LJ, Smith RP, Brett BT, Rogers LM, Scheetz TE, Dupuy AJ. Sequencing methods and datasets to improve functional interpretation of sleeping beauty mutagenesis screens. BMC Genomics. 2014 Dec 19; 15:1150
    View PubMed
  4. Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer. Immunol Res. 2014 Aug; 59 (1-3):203-10
    View PubMed
  5. Gibson-Corley KN, Rogers LM, Goeken A, Dupuy AJ, Meyerholz DK. Keratoacanthoma Pathobiology in Mouse Models. Diseases. 2014 May 23; 2 (2):106-119
    View PubMed
  6. Rogers LM, Riordan JD, Swick BL, Meyerholz DK, Dupuy AJ. Ectopic expression of Zmiz1 induces cutaneous squamous cell malignancies in a mouse model of cancer. J Invest Dermatol. 2013 Jul; 133 (7):1863-9 Epub 2013 Feb 20
    View PubMed
  7. Rogers LM, Olivier AK, Meyerholz DK, Dupuy AJ. Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer. J Immunol. 2013 Apr 15; 190 (8):4393-9 Epub 2013 Mar 08
    View PubMed
  8. Dupuy AJ, Rogers LM, Kim J, Nannapaneni K, Starr TK, Liu P, Largaespada DA, Scheetz TE, Jenkins NA, Copeland NG. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res. 2009 Oct 15; 69 (20):8150-6 Epub 2009 Oct 06
    View PubMed